Good Morning Investors!!! Yesterday ended with a small pullback as tech cooled off, oil jumped, and investors kept a close eye on interest rates. The big moment today is at 2:00 PM ET when the Federal Reserve meeting notes hit, since even a few “higher for longer” hints can move bond yields and stock mood fast. We’re also digging into Meta’s fresh artificial intelligence deal and what it could mean for the next wave of “do-stuff” tools inside apps. Plus, we spotlight medical devices, a steady corner of healthcare that tends to shine when surgery demand is up.
Key Market DriversTech cools off near the finish line: Stocks slipped at Monday’s close: the Dow Jones Industrial Average (Dow) fell 0.5%, the S&P 500 lost 0.4%, and Nasdaq fell 0.5%. Most sectors were red, with tech leading the slide.Early Tuesday, stock futures were close to flat, hinting that Monday’s tech-led dip may cool off. Big tech still owns the steering wheel, so headlines in artificial intelligence (AI) can swing moods fast even in a quiet holiday week. 
S&P 500 1 Year Price Chart
Rates stay in the spotlight: Bond yields eased, with the 10-year U.S. Treasury yield ending Monday around 4.106%. That yield is basically the market’s “price tag” on money, and it matters because it shapes mortgage rates, loan rates, and what investors demand from stocks too. Today, we get minutes from the Federal Reserve meeting that cut rates by 25 basis points and hinted at a pause. Hawkish (higher-rate tone) minutes can lift yields; job-focused minutes can perk up stocks. Oil jumps, gold gets the jitters: Oil prices jumped, with West Texas Intermediate settling near $58 a barrel after fresh supply worries and world tension. Energy prices can feed into inflation, and inflation can steer interest rates, so oil’s move can ripple from gas pumps to stock prices. Gold slid about 4.5% from record highs, a classic “lock in the win” move after a big run. When traders sell safe havens (stuff people buy when scared) like gold, it can hint at calmer nerves, or just year-end cleanup. Global stocks still look perky: Overseas, Europe kept flexing, with the STOXX Europe 600 (broad Europe stock index) near a record as banks and miners led gains. A big theme is money moving from pricey U.S. tech into other regions and sectors. In Hong Kong, several Chinese firms popped on debut after initial public offerings, raising $900 million. That hints risk appetite for China-linked growth is warming, even though mood can flip fast. |
Thoughts from InvestorsGrow:
The big one today is the Fed minutes at 2:00 PM. Think of it like the “director’s cut” of the meeting. Investors will look for how split the group was, and what it would take to cut (or not cut) rates again. If the tone sounds more hawkish, bond yields (the interest rate investors get) can rise and stocks can feel a headwind. If it sounds more dovish, yields can slip and stocks can exhale.
Tomorrow morning’s jobless claims are the quick pulse check. A jump can spook people about jobs, while a low number can back the “economy is okay” story. One big note: holiday weeks can cause weird bumps, so do not treat one print like a crystal ball. Also, New Year’s Eve trading can be sleepy, so a small push can look like a big shove.
Medical Devices
Medical devices are the tools that help doctors test, track, and treat patients. Think knee implants, heart stents, and surgical robots. Demand is tied to aging and care, so this group can be steadier than many “hot trend” stocks.
One way to track the space is an exchange-traded fund (ETF), such as the iShares U.S. Medical Devices ETF (IHI). IHI closed near $62.62 on Dec 29 and was up about 8.04% since Jan 1. A key theme is focus: Medtronic filed paperwork to take its MiniMed diabetes business public in 2026.
Intuitive Surgical (ISRG):
Now I know we had this company in yesterdays morning note, but it fits nicely here as well so once again…. ISRG sells the da Vinci platform, a leading system for robot-assisted surgery. Its edge is a huge installed base plus repeat sales of tools and service each time the system is used. Watch new system rollouts, since a slower upgrade cycle can cool growth.
Medtronic (MDT):
This is a large maker of devices for the heart, brain, spine, and diabetes care. Its scale helps it fund research and sell across many hospital departments at once. The near-term catalyst is the planned MiniMed U.S. initial public offering (IPO), but big splits can add execution risk.
Smith & Nephew (SNN):
This UK-based firm sells ortho implants, sports medicine gear, and wound care. Its mix can smooth bumps when one product line slows. It recently set new growth and cash flow targets, and the market will watch if U.S. knee sales improve.
Stryker (SYK):
It makes medical gear and implants for joint work, trauma care, and hospitals. Its “secret sauce” is the Mako system, a robot tool used in knee and hip surgery that helps surgeons plan and place implants with more care. Stryker also sells the implants and tools that go with it, which can make hospitals stick with the same setup over time. In its most recent quarter, organic sales rose about 9.5%, and the company raised its full-year growth view, which suggests surgery demand is still holding up.
InvestorsGrow Takeaway:
Med tech tends to do best when surgery volume is rising and hospitals are spending. If you are tracking the space, follow procedure trends and major product launches, not day-to-day noise.
Meta Platforms (META)
Meta Platforms (META) runs Facebook, Instagram, and WhatsApp. It makes most of its money from ads, so it lives and dies by how much time people spend in its apps.
Late Monday, Meta said it will buy Manus, a Singapore-based artificial intelligence (AI) start-up known for an “AI agent” tool. (AI agent: software that can plan and act for you.) The price was not shared, but people close to the deal put it around $2 billion to $3 billion. That is a sharp jump from a roughly $500 million tag in a funding round earlier this year.
Why it matters is simple. Meta wants AI that does work, not just chat. Think of a helper that can pull info, draft a plan, and set up tasks for a team, all inside Meta’s apps. If this hits, it can help Meta keep users and give businesses more reasons to pay.
META shares were down about 0.7% in early trading. What to watch next is how fast new features ship, and if Meta can charge for them while keeping trust high on privacy.
InvestorsGrow Takeaway:
Meta is a cash-rich ad giant, and AI is the next layer of glue for its apps. Buying a ready-made “do stuff” tool could speed up new products and new fees. The red flags are big AI bills, fuzzy payback, and more heat from regulators on data. Keep an eye on costs and proof that real users are paying.
